CannabisNCT06595576
Cannabis Edibles and Simulated Driving
A study testing Cannabis - Low Dose (2 mg), Cannabis - Medium Dose (10 mg) and Cannabis - High Dose (20 mg) in people with Cannabis and Driving Under the Influence, run by Centre for Addiction and Mental Health at 1 site in Canada.
Trial summary
The goal of this human laboratory experiment is to determine the acute and residual effects of a range of doses of orally administered cannabis edibles on driving simulator performance in people who use cannabis recreationally. Four conditions will be tested: placebo, low dose, medium dose and high dose. Read more about this study
- Who is it for?
- Ages 19 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Cannabis, Driving Under the Influence
- What is being tested?
- Cannabis - Low Dose (2 mg), Cannabis - Medium Dose (10 mg) and Cannabis - High Dose (20 mg)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 52 participants
- Where
- 1 siteCanada
- Study dates
- 1 Oct 2024to 4 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Provides written and informed consent
- Stated the willingness to comply with all study procedures
- Recreational use of oral, vaped, smoked or edible cannabis (at least one day/week) and cannabis edibles (at least one day/month) confirmed by self-report and urine screening (i.e., positive THC result in point-of-care screening or Clinical Laboratory assay)
- Males and females aged 19 to 45 years
- Has held a class G license (or equivalent from another jurisdiction) for at least 12 months
- Willing to abstain from using cannabis for 72 hours prior to each practice or test session
Show all 11Show fewer
- Willing to abstain from alcohol for 48 hours prior to each practice or test session, and to abstain from all other drugs not medically required for the duration of the study (beginning 48 hours prior to the practice session)
- Lives within a radius that costs less than about $60 per taxi ride
- Able to consume the quantity of candies and drive the driving simulator as determined by a practice session
- A negative urine pregnancy test for those with childbearing potential
- Use of appropriate contraception for those with childbearing potential
Who cannot join
- Diagnosis of severe medical or psychiatric condition (e.g., diagnosis of a severe mood or anxiety disorder, based on self-report
- Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder
- Regular user of medication that may affect cognitive functioning and/or driver performance (e.g. ADHD medication, benzodiazepines, stimulants, opioids)
- Regular user of illicit substances
- Personal or family history of schizophrenia or other psychotic disorder
- Pregnant, looking to become pregnant, or breastfeeding
Show all 11Show fewer
- Concomitant therapy with sedative-hypnotics or other psychoactive drugs
- Severe laboratory abnormalities that could create safety issues based on the judgement of the Principal Investigator
- Cardiovascular or cerebrovascular disease
- Severe renal or liver disease
- Participation in another clinical or non-therapeutic study in the past month
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dose-dependent Effects of Cannabis Edibles on Simulated Driving Performance
The goal of this human laboratory experiment is to determine the acute and residual effects of a range of doses of orally administered cannabis edibles on driving simulator performance in people who use cannabis recreationally. Four conditions will be tested: placebo, low dose, medium dose and high dose. Driving performance will be tested objectively using a driving simulator during a number of pre-programmed driving scenarios. The investigators will test the hypothesis that driving performance on a high-fidelity driving simulator will decrease with increasing doses of cannabis. Secondary objectives will:
- Determine the acute and residual (24 hour) cognitive, behavioural, and physiological effects of a range of doses of orally administered cannabis edibles on subjective effects, cognitive tests, verbal memory, and mood.
- Examine how the concentration of THC in blood and oral fluids correlates with driving simulator performance, as well as cognitive, behavioural, and physiological measures. Cannabinoid levels in blood, urine and oral fluids will be measured at baseline and over a 5 hour period following drug exposure. The investigators will examine the relationship between cannabinoid levels and performance measures in this time frame.
- Explore potential biomarkers of acute exposure to cannabis edibles by analyzing the following: circulating cell-free mtDNA (ccf-mtDNA), endocannabinoids, and metabolic biomarkers.
- Conditions
- Cannabis, Driving Under the Influence
- Being tested
- Cannabis - Placebo Dose (0 mg), Cannabis - Low Dose (2 mg), Cannabis - Medium Dose (10 mg), Cannabis - High Dose (20 mg)
- Keywords
- Cannabis Edibles, THC, Driving Simulator, Cognition, Subjective Effects, Cannabinoids
- Medical subject headings
- Marijuana Abuse, Driving Under the Influence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cannabis - Placebo Dose (0 mg)Drug
Participants will consume placebo cannabis edibles.
Cannabis - Low Dose (2 mg)Drug
Participants will consume a low dose (2 mg) of cannabis edibles.
Cannabis - Medium Dose (10 mg)Drug
Participants will consume a medium dose (10 mg) of cannabis edibles.
Cannabis - High Dose (20 mg)Drug
Participants will consume a high dose (20 mg) of cannabis edibles.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Cannabis Edibles (0 mg THC) | Experimental | Participants consume a placebo dose of cannabis edibles (0 mg THC). Receives: Drug: Cannabis - Placebo Dose (0 mg) |
| Low Dose Cannabis Edibles (2 mg THC) | Experimental | Participants consume a low dose of cannabis edibles (2 mg THC). Receives: Drug: Cannabis - Low Dose (2 mg) |
| Medium Dose Cannabis Edibles (10 mg) | Experimental | Participants consume a medium dose of cannabis edibles (10 mg THC). Receives: Drug: Cannabis - Medium Dose (10 mg) |
| High Dose Cannabis Edibles (20 mg) | Experimental | Participants consume a high dose of cannabis edibles (20 mg THC). Receives: Drug: Cannabis - High Dose (20 mg) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Standard Deviation of Lateral Position (SDLP)
The driving simulator will objectively record SDLP during a number of pre-programmed driving scenarios.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Secondary outcomes (14)
Mean Speed (MS)
The driving simulator will objectively record MS during a number of pre-programmed driving scenarios.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Reaction Time (RT)
The driving simulator will objectively record RT during a number of pre-programmed driving scenarios.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Standard Deviation of Speed (SDS)
The driving simulator will objectively record SDS during a number of pre-programmed driving scenarios.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood concentrations of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH)
Used to assess THC and metabolite concentrations (ng/mL) in blood.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Oral fluid concentrations of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and point-of-care detection of cannabinoids
Used to assess THC and metabolite concentrations (ng/mL) in oral fluid.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Heart Rate
Heart rate (bpm) will be measured.
Measured: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Blood Pressure
Systolic and diastolic blood pressure (mmHg) will be measured.
Measured: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Temperature
Temperature (degrees Celsius) will be measured.
Measured: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Visual Analog Scale (VAS)
Used to assess subjective effects of cannabis on a sliding scale of 0 (not at all) to 100 (maximum effect).
Measured: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Addiction Research Centre Inventory (ARCI)
Used to assess subjective effects of cannabis.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Profile of Mood States (POMS)
Used to assess subjective effects of cannabis.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Verbal Free Recall Task
Used to assess the impact of cannabis on verbal learning and memory.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood Concentrations of mtDNA
Used to assess concentrations of mtDNA.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood Concentrations Endocannabinoids
Used to assess concentrations of endocannabinoids.
Measured: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start1 Oct 2024
- Primary completion4 Apr 2025
- Study completion4 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CannabisStudies of the same condition, open and under way.
- More trials run by Centre for Addiction and Mental HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The study will be a within-subjects, double-blind, placebo-controlled, randomized and counterbalanced human laboratory experiment assessing the effects of a range of doses of cannabis edibles on driving simulator performance. These 4 drug exposure conditions are: placebo, low dose (2 + 2% mg THC), medium dose (10 + 2% mg THC), and high dose (20 + 2% mg THC).
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 52 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Bernard Le Foll, MD, PhD, Principal investigator, Centre for Addiction and Mental Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06595576
- Sponsor's protocol ID
- 074-2020
- Status last verified
- Feb 2025
- First submitted
- 6 Sep 2024
- Last updated
- 3 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Le Foll B, Matheson J, Antwi P, Wright M, Zaweel A, Hasan OSM, Kloiber S, Hassan AN, Sproule B, Wickens CM, Di Ciano P, Brands B. Dose-Dependent Effects of Cannabis Edibles on Simulated Driving Performance: A Randomized Clinical Trial. JAMA Netw Open. 2026 Aug 3;9(8):e2631306. doi: 10.1001/jamanetworkopen.2026.31306.
PubMed 42671837
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-dependent Effects of Cannabis Edibles on Simulated Driving Performance
- ClinicalTrials.gov ID
- NCT06595576
- Acronym / sponsor ID
- 074-2020
- Conditions
- Cannabis, Driving Under the Influence
- Keywords
- Cannabis Edibles, THC, Driving Simulator, Cognition, Subjective Effects, Cannabinoids
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 52 participants (actual)
- Lead sponsor
- Centre for Addiction and Mental HealthUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 4 Apr 2025 (actual)
- Study completion
- 4 Apr 2025 (actual)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this human laboratory experiment is to determine the acute and residual effects of a range of doses of orally administered cannabis edibles on driving simulator performance in people who use cannabis recreationally. Four conditions will be tested: placebo, low dose, medium dose and high dose. Driving performance will be tested objectively using a driving simulator during a number of pre-programmed driving scenarios. The investigators will test the hypothesis that driving performance on a high-fidelity driving simulator will decrease with increasing doses of cannabis. Secondary objectives will:
- Determine the acute and residual (24 hour) cognitive, behavioural, and physiological effects of a range of doses of orally administered cannabis edibles on subjective effects, cognitive tests, verbal memory, and mood.
- Examine how the concentration of THC in blood and oral fluids correlates with driving simulator performance, as well as cognitive, behavioural, and physiological measures. Cannabinoid levels in blood, urine and oral fluids will be measured at baseline and over a 5 hour period following drug exposure. The investigators will examine the relationship between cannabinoid levels and performance measures in this time frame.
- Explore potential biomarkers of acute exposure to cannabis edibles by analyzing the following: circulating cell-free mtDNA (ccf-mtDNA), endocannabinoids, and metabolic biomarkers.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- The study will be a within-subjects, double-blind, placebo-controlled, randomized and counterbalanced human laboratory experiment assessing the effects of a range of doses of cannabis edibles on driving simulator performance. These 4 drug exposure conditions are: placebo, low dose (2 + 2% mg THC), medium dose (10 + 2% mg THC), and high dose (20 + 2% mg THC).
| Arm | Type | Receives |
|---|---|---|
| Placebo Cannabis Edibles (0 mg THC) | Experimental | Drug: Cannabis - Placebo Dose (0 mg)Participants consume a placebo dose of cannabis edibles (0 mg THC). |
| Low Dose Cannabis Edibles (2 mg THC) | Experimental | Drug: Cannabis - Low Dose (2 mg)Participants consume a low dose of cannabis edibles (2 mg THC). |
| Medium Dose Cannabis Edibles (10 mg) | Experimental | Drug: Cannabis - Medium Dose (10 mg)Participants consume a medium dose of cannabis edibles (10 mg THC). |
| High Dose Cannabis Edibles (20 mg) | Experimental | Drug: Cannabis - High Dose (20 mg)Participants consume a high dose of cannabis edibles (20 mg THC). |
Who may qualify
- Ages
- 19 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Provides written and informed consent
- Stated the willingness to comply with all study procedures
- Recreational use of oral, vaped, smoked or edible cannabis (at least one day/week) and cannabis edibles (at least one day/month) confirmed by self-report and urine screening (i.e., positive THC result in point-of-care screening or Clinical Laboratory assay)
- Males and females aged 19 to 45 years
- Has held a class G license (or equivalent from another jurisdiction) for at least 12 months
Key exclusion criteria (11 listed)
- Diagnosis of severe medical or psychiatric condition (e.g., diagnosis of a severe mood or anxiety disorder, based on self-report
- Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder
- Regular user of medication that may affect cognitive functioning and/or driver performance (e.g. ADHD medication, benzodiazepines, stimulants, opioids)
- Regular user of illicit substances
- Personal or family history of schizophrenia or other psychotic disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cannabis - Placebo Dose (0 mg)Participants will consume placebo cannabis edibles. | Drug | Placebo Cannabis Edibles (0 mg THC) |
| Cannabis - Low Dose (2 mg)Participants will consume a low dose (2 mg) of cannabis edibles. | Drug | Low Dose Cannabis Edibles (2 mg THC) |
| Cannabis - Medium Dose (10 mg)Participants will consume a medium dose (10 mg) of cannabis edibles. | Drug | Medium Dose Cannabis Edibles (10 mg) |
| Cannabis - High Dose (20 mg)Participants will consume a high dose (20 mg) of cannabis edibles. | Drug | High Dose Cannabis Edibles (20 mg) |
Primary outcome
Standard Deviation of Lateral Position (SDLP)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
The driving simulator will objectively record SDLP during a number of pre-programmed driving scenarios.
14 secondary outcomes
Mean Speed (MS)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Reaction Time (RT)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Standard Deviation of Speed (SDS)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood concentrations of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Oral fluid concentrations of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-Δ9-tetrahydrocannabinol (OH-THC), and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and point-of-care detection of cannabinoids
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Heart Rate
Time frame: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Blood Pressure
Time frame: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Temperature
Time frame: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Visual Analog Scale (VAS)
Time frame: Before cannabis exposure; 0, 30, 60, 90 minutes and 2, 3, 4 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated approximately 24 hours after dosing.
Addiction Research Centre Inventory (ARCI)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Profile of Mood States (POMS)
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Verbal Free Recall Task
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood Concentrations of mtDNA
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Blood Concentrations Endocannabinoids
Time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
- Derived from this study: PubMed 42671837Le Foll B, Matheson J, Antwi P, Wright M, Zaweel A, Hasan OSM, Kloiber S, Hassan AN, Sproule B, Wickens CM, Di Ciano P, Brands B. Dose-Dependent Effects of Cannabis Edibles on Simulated Driving Performance: A Randomized Clinical Trial. JAMA Netw Open. 2026 Aug 3;9(8):e2631306. doi: 10.1001/jamanetworkopen.2026.31306.
Related trials for Cannabis
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
Not yet recruitingPhase 1
PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis
Cigarette Smoking-Related Carcinoma
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bernard Le Foll, MD, PhD principal investigator
Centre for Addiction and Mental Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cannabis - Low Dose (2 mg), Cannabis - Medium Dose (10 mg) and Cannabis - High Dose (20 mg) in people with Cannabis and Driving Under the Influence, run by Centre for Addiction and Mental Health at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Standard Deviation of Lateral Position (SDLP) (time frame: Before cannabis exposure; 2 and 5 hours after cannabis exposure (repeated each session for 4 sessions). Also repeated on the test for residual effects, approximately 24 hours after dosing.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06595576, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.